State Street Corp Has $136.02 Million Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

State Street Corp increased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 3.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,858,915 shares of the biopharmaceutical company's stock after buying an additional 56,664 shares during the quarter. State Street Corp owned about 1.75% of Intra-Cellular Therapies worth $136,017,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of ITCI. Quarry LP increased its holdings in shares of Intra-Cellular Therapies by 260.0% in the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company's stock valued at $132,000 after buying an additional 1,300 shares in the last quarter. Parkman Healthcare Partners LLC lifted its holdings in shares of Intra-Cellular Therapies by 30.6% during the third quarter. Parkman Healthcare Partners LLC now owns 241,575 shares of the biopharmaceutical company's stock valued at $17,676,000 after purchasing an additional 56,547 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Intra-Cellular Therapies by 6.4% in the 3rd quarter. Janus Henderson Group PLC now owns 42,729 shares of the biopharmaceutical company's stock valued at $3,126,000 after purchasing an additional 2,568 shares during the period. HighTower Advisors LLC acquired a new position in shares of Intra-Cellular Therapies in the 3rd quarter valued at $280,000. Finally, Erste Asset Management GmbH purchased a new position in Intra-Cellular Therapies in the 3rd quarter worth about $1,715,000. Institutional investors own 92.33% of the company's stock.

Intra-Cellular Therapies Trading Down 0.4 %

Shares of ITCI traded down $0.37 during trading hours on Friday, hitting $83.03. 366,657 shares of the stock traded hands, compared to its average volume of 828,507. The business has a fifty day moving average of $82.44 and a 200-day moving average of $76.84. The firm has a market capitalization of $8.80 billion, a PE ratio of -95.44 and a beta of 0.95. Intra-Cellular Therapies, Inc. has a 1-year low of $62.78 and a 1-year high of $93.45.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The business had revenue of $175.40 million for the quarter, compared to analyst estimates of $172.30 million. During the same quarter in the prior year, the firm earned ($0.25) EPS. The firm's quarterly revenue was up 39.0% compared to the same quarter last year. As a group, equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Insider Activity at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, President Michael Halstead sold 22,869 shares of the stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total transaction of $2,038,085.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Sharon Mates sold 51,000 shares of the business's stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. The trade was a 4.55 % decrease in their position. The disclosure for this sale can be found here. 2.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Royal Bank of Canada upped their price target on Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an "outperform" rating in a research report on Friday, October 4th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $130.00 target price on shares of Intra-Cellular Therapies in a research note on Monday, September 16th. Needham & Company LLC restated a "buy" rating and issued a $100.00 price objective on shares of Intra-Cellular Therapies in a research note on Wednesday, October 30th. Morgan Stanley lifted their price objective on Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an "overweight" rating in a report on Friday, October 11th. Finally, Piper Sandler raised Intra-Cellular Therapies from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $68.00 to $92.00 in a report on Friday, September 6th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat, Intra-Cellular Therapies presently has a consensus rating of "Moderate Buy" and an average price target of $97.23.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.